BRIEF published on 03/14/2025 at 17:50, 22 days 12 hours ago Median Technologies Maintains its Eligibility for the PEA-PME Scheme PEA-PME Euronext Growth Tax Benefits Eligibility Median Technologies
BRIEF published on 02/24/2025 at 17:50, 1 month 9 days ago Median Technologies: Presentation of eyonis™ LCS at ECR 2025 Artificial Intelligence Median Technologies Lung Cancer Eyonis™ LCS ECR 2025
BRIEF published on 01/31/2025 at 08:05, 2 months 5 days ago Median Technologies unveils its 2024 financial results and its 2025 outlook Financial Results FDA Approval Median Technologies Eyonis™ LCS Expansion 2025
PRESS RELEASE published on 01/31/2025 at 08:00, 2 months 5 days ago Inside Information / Other news releases Median Technologies reports 2024 financial indicators and 2025 outlook, including eyonis™ LCS FDA clearance and iCRO revenue growth. Strategic milestones and new financing agreements drive towards 2025 goals Financial Indicators Median Technologies Eyonis LCS 2025 Outlook ICRO Revenue Growth
BRIEF published on 01/24/2025 at 08:05, 2 months 12 days ago Median Technologies Secures Up to €47.5 Million for AI Lung Cancer Diagnostics European Investment Bank Median Technologies AI Lung Cancer Diagnostics Eyonis™ EU And US Commercialization
PRESS RELEASE published on 01/24/2025 at 08:00, 2 months 12 days ago Inside Information / Other news releases Median Technologies secures up to €47.5 million for eyonis™ AI lung cancer diagnostic regulatory filings & U.S./EU commercialization. New financing & operational enhancements drive profitability & extend cash runway into Q4, 2025 AI Commercialization Median Technologies Lung Cancer Diagnostic Eyonis
BRIEF published on 11/26/2024 at 17:50, 4 months 9 days ago Median Technologies Showcases AI Lung Cancer Diagnostic at RSNA 2024 Clinical Trials Eyonis™ LCS RSNA 2024 AI-powered Diagnostics Lung Cancer Screening
PRESS RELEASE published on 11/26/2024 at 17:45, 4 months 9 days ago Inside Information / Other news releases Median Technologies to showcase AI-powered lung cancer diagnostic eyonis™ LCS at RSNA 2024. Company presents latest developments and REALITY study results to experts in medical imaging conference AI-powered Median Technologies Eyonis LCS RSNA 2024 Lung Cancer Diagnostic
BRIEF published on 10/30/2024 at 17:50, 5 months 6 days ago Median Technologies and AI in lung cancer screening Artificial Intelligence Medical Technologies Lung Cancer Webconférence 2024 Medical Screening
BRIEF published on 10/07/2024 at 17:50, 5 months 29 days ago Status of voting rights and capital of Median Technologies as of September 30, 2024 Voting Rights Capital Actions Median Technologies September 30, 2024
Published on 04/05/2025 at 01:50, 1 day 4 hours ago Battery X Metals Achieves Graphite Recovery Breakthrough in Partnership with Global Top 20 University in Controlled Trials
Published on 04/04/2025 at 18:51, 1 day 11 hours ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 04/04/2025 at 18:30, 1 day 12 hours ago Forbo shareholders approved all proposals of the Board of Directors
Published on 04/04/2025 at 18:11, 1 day 12 hours ago Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 04/04/2025 at 18:00, 1 day 12 hours ago Sartorius to acquire microtissue business MatTek from Swedish BICO AB
Published on 04/04/2025 at 17:40, 1 day 13 hours ago Genel Energy PLC: Update on arbitration regarding the Bina Bawi and Miran PSCs / Recoverable Costs Award
Published on 04/04/2025 at 19:18, 1 day 11 hours ago Mersen: Number of shares and voting rights as of March 31, 2025
Published on 04/04/2025 at 18:17, 1 day 12 hours ago Reporting on share buyback transactions carried out between March 31 and April 3, 2025
Published on 04/04/2025 at 18:13, 1 day 12 hours ago Total number of voting rights and shares making up the share capital at March 31, 2025
Published on 04/04/2025 at 17:45, 1 day 13 hours ago imerys-04-04-2025-regulated-information-publication-of-the-meeting-notice
